Selexys Pharmaceuticals Corporation;Oklahoma Medical Research Foundation
发明人:
Rollins, Scott,Alvarez, Richard,Rother, Russell,Kawar, Ziad S.,McEver, Rodger P.
申请号：
AU2016262660
公开号：
AU2016262660A1
申请日:
2016.11.22
申请国别(地区):
AU
年份:
2016
代理人:
摘要：
#$%^&*AU2016262660A120161208.pdf#####ABSTRACT Antibodies are disclosed which bind specifically to P-selectin, block the binding of PSGL-1 to P-selectin, and cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such dual function anti-Pselectin antibodies and binding fragments thereof may be used in the treatment of a variety of acute and chronic inflammatory and thrombotic disorders and conditions. Screening methods for identifying and characterizing such antibodies are also disclosed.
